« Return to News | Technology Solutions

etrials Ends 'Challenging Year,' Reports $15.8M Loss

Friday, March 6, 2009 07:59 AM

In what CEO M. Denis Connaghan called a "challenging year," eClinical company etrials reported a decrease in year-end revenue and an operating loss for the year.

Net service revenue for the year was $15.1 million, down from $18.3 million in 2007. The company reported a net loss attributable to common stockholders’ of $15.8 million, or $1.45 per share, compared to a net loss of $6.2 million or $0.57 per share in 2007.

Net service revenues for the fourth quarter were also down at $3.6 million compared with $4.9 million for the same period 2007. Net loss for the fourth quarter of 2008 was $5.5 million or $0.50 per share, compared with a net loss of $2.6 million, or $0.24 per share in the fourth quarter of 2007.

The eClinical company posted losses for very quarter of 2008 and lost three senior executives (CEO, COO and CFO) last summer.

"Unfavorable economic conditions are forcing many of our life sciences and pharmaceutical customers to reevaluate their priorities at times resulting in them moving forward only on those trials which have the greatest chance for success, delaying work on others," Connaghan said.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.